September - 2018

MECFA Blog

Dietary Flavonoids May Help in Managing CF Through Impact on Gut Bacteria, Small Study Suggests

Consuming dietary flavonoids — compounds naturally found in fruits, vegetables, chocolate, and beverages like wine and tea — may be...

Take the MECFA Survey!

Dear MECFA Members and Friends, The Middle East Cystic Fibrosis Association (MECFA) is non profit organization dedicated to improving...

Vertex and Treating CF: 3 Disease-modifying Therapies Make Leap from Lab to Patients

Editor’s Note: This is the second of a four-part series looking at Vertex Pharmaceuticals and its “all in for CF” approach. Here, we...

Discovering the ancient origin of cystic fibrosis, the most common genetic disease in Caucasians

Imagine the thrill of discovery when more than 10 years of research on the origin of a common genetic disease, cystic fibrosis (CF),...

Vertex and Treating CF: Stepping Out on Long Road to ‘Medical History’

Editor’s note: This is the first of a four-part series looking at Vertex Pharmaceuticals and its “all in for CF” approach. We begin by...

Telavancin Promising Potential Treatment Option for MRSA in Cystic Fibrosis Patients

Responsible for several issues ranging from skin infections and sepsis to pneumonia and bloodstream infections, methicillin-resistant...

Committee approves 8 additional conditions for treatment with medical marijuana

A legislative committee approved eight additional conditions — six just for adults and two for adults and children — that will soon be...

MRSA Difficult to Eradicate, Even With Multimodal Antibiotics, CF Study Finds

Up to one month of treatment with inhaled vancomycin, the antibiotic of choice for treating most methicillin-resistant Staphylococcus...

DarioHealth Chosen by Attain Health for Pilot Study to Improve Cystic Fibrosis Related Diabetes Mana

- Opportunity for DarioHealth to take early lead in deploying digital health solution for this unique form of diabetes common in people...

FDA Expands Kalydeco’s Approval to 1-year-old Toddlers with Cystic Fibrosis

The U.S. Food and Drug Administration (FDA) has approved Kalydeco (ivacaftor) as the first-ever therapy to treat the underlying cause of...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p